AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03524703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chewing gum
Description: Chewing gum four times per day for 5 days, 15 minutes each time.
Study NCT04460664 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study NCT04359368 — intervention group
Intervention type: OTHER
Intervention: collection of patient data
Description: Data collection (history, clinical presentation, medication, complications, laboratory testing) will be performed from patient records stored in the protected electronic patient system ISMed (Integrated System for Medical Diagnostic) of patients with HSRs to NDIPs.
Study NCT01559311 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT-P OFF
Description: CRT Pacemaker
Study NCT01559311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT-P ON
Description: CRT Pacemaker
Study NCT01559311 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DDDR
Description: Dual-chamber, rate-modulated pacemaker
Study NCT03240627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LH-8
Description: LH-8 cutaneous solution
Study NCT03240627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cutaneous solution
Study NCT00733343 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Europe: AutoSet CS (USA: VPAP Adapt SV)
Description: At least 3 hours average daily usage time
Study NCT02423941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrogade reperfusion
Description: Retrogade caval reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
Study NCT02423941 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antegrade reperfusion
Description: Antegrade conventional portal reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
Study NCT04352140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetragraph
Description: FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin electrodes.
Study NCT04352140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ToFscan
Description: ToFscan is a nerve stimulator module used for the measurement of neuromuscular transmission via accelerometry. ToFscan was developed by Drager Technologies, Canada, and it uses a three-dimensional piezoelectric sensor that attaches to the thumb via a hand adapter to measure acceleration in multiple planes (Murphy et al, 2018). Following simultaneous ulnar nerve stimulation on each arm, the response of the adductor pollicis will be measured
Study NCT03132948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Nintendo WII fit console, Xbox console, sport activities (soccer, basketball, yoga, walking and other physical games)
Study NCT03078946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride
Description: 30 patients received a loading dose of 1 μg/kg dexmedetomidine (Precedex; Hospira, Precedex 200 mcg/2 ml, Hospira. Inc, Lake Forest, USA) diluted in 100 ml 0.9% saline infused over 10 min immediately postoperative, followed by continuous infusion of 0.2- 0.7 μg/kg/h
Study NCT03078946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine and Midazolam
Description: 30 patients received morphine in a dose of 10-50μg/ kg/hr as an analgesic (Morphine Sulphate ampoule; 10 mg/ 1ml, Misr Co.- Egypt) with midazolam in a dose of 0.05mg/kg up to 0.2 mg/kg (Dormicum; Roche; USA; ampoule containing 15 mg/3 ml mixed in sugar-free apple juice limiting the total volume mixed with a double volume of apple juice) repeated as needed.
Study NCT03791658 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The 12-question TAI
Description: The 12-question TAI (Test for the Adherence to Inhalers) yields a score indicating level of adherence (high, intermediate or poor). The TAI also provides some indication about the possible mechanisms of non-adherence (sporadic, deliberate or unconscious).
Study NCT03791658 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Information from patients file
Description: Depending on which arm or group specific information will be gathered from the patients file after informed consent.
Study NCT03791658 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The Asthma Control Test (ACT)
Description: An international validated questionnaire on the symptoms an asthmatic experiences and the disease control in the patient. Only for the Asthmatics arm of the study
Study NCT03791658 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The COPD Assessment Test (CAT)
Description: An international validated questionnaire on the symptoms a COPD-patient experiences and the disease control in the patient. Only for the COPD arm of the study
Study NCT02202928 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK
Description: 8×10\^9 autologous tumor lysate pulsed DC-CIK cells for each infusion, IV (in the vein) for four cycles, each cycle received four infusions with a 1 day interval.
Study NCT02202928 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Radiotherapy
Description: 45\~50 Gy in 25-28 fractions.
Study NCT02202928 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 45\~50 Gy in 25-28 fractions.
Study NCT02202928 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Chemotherapy
Description: Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
Study NCT02202928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
Study NCT00006125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00006125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study NCT00926809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin
Description: Lansoprazole, Amoxicillin 1000 mg, Clarithromycin 500 mg
Study NCT00926809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lansoprazole (proton pump inhibitor), placebo
Description: Lansoprazole, Amoxicillin placebo, Clarythromycin placebo
Study NCT00448422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prulifloxacin
Description: Tablet
Study NCT00448422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prulifloxacin
Description: Tablet
Study NCT04587622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icenticaftor
Description: Single oral dose of 300 mg of icenticaftor (QBW251)
Study NCT03571516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: SC injection of 0.05 mg/kg teduglutide will be administered QD into abdomen or into either the thigh or arm for 24 weeks.
Study NCT03571516 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Medical Therapy
Description: Standard medical therapy will be administered for 24 weeks.
Study NCT03571516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: Standard medical therapy will be administered for 24 weeks.
Study NCT03571516 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Syringe
Description: Teduglutide will be administered using syringe (510k number: K980987).
Study NCT03571516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe
Description: Teduglutide will be administered using syringe (510k number: K980987).
Study NCT03571516 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Needle
Description: Teduglutide will be administered using needle (510k number: K021475).
Study NCT03571516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle
Description: Teduglutide will be administered using needle (510k number: K021475).
Study NCT02659332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TURBT
Description: Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of 1 ms)
Study NCT02143843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Description: Bimatoprost Ocular Insert used continuously for 7 months, then replaced with a new Bimatoprost Ocular Insert and used continuously for another 6 months.
Study NCT02482350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading Training
Description: Healthy subjects read moving (scrolling) text faster than static text. This type of text, also called Times Square presentation, induces a form of involuntary eye movement called optokinetic nystagmus (OKN) in the reader and, when used as part of a rehabilitation program, has been shown to improve subsequent reading performance of static text.
Study NCT01037790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: Given orally, 125 mg QD on a 21-day
Study NCT03299192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Yang Style Tai Chi
Study NCT03299192 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Comprehensive Health Education relevant for Healthy Aging in Patients with Chronic Back Pain
Study NCT03299192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Medical Care
Description: Medications, PT, Complementary and Integrative Health and other miscellaneous treatments as appropriate.
Study NCT03299192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Medical Care
Description: Medications, PT, Complementary and Integrative Health and other miscellaneous treatments as appropriate.
Study NCT01482260 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy
Description: Biopsy
Study NCT00850031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcuFocus Corneal Inlay
Description: Inlay implanted in cornea for improvement of near vision
Study NCT04584710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTB101
Description: Oral RTB101 10 mg hard gelatin capsule once daily for 2 weeks
Study NCT04584710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral matching placebo once daily for 2 weeks
Study NCT02915614 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: 3-weeks of inpatient pulmonary Rehabilitation including exercise Training (daily endurance and strength Training)
Study NCT02915614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: 3-weeks of inpatient pulmonary Rehabilitation including exercise Training (daily endurance and strength Training)
Study NCT02281136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid (ALA)
Description: 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
Study NCT02281136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLU-U
Description: 10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
Study NCT01791361 — intervention group
Intervention type: OTHER
Intervention: Other
Description: No intervention other than routine medical care
Study NCT00898976 — intervention group
Intervention type: OTHER
Intervention: immunohistochemistry staining method
Study NCT00898976 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study NCT00378703 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV
Study NCT00378703 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00378703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00378703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00378703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00378703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00378703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT00378703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT02677792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Family Intervention (BFI)
Description: Participating families will receive standard medical care through the Wellness and Weight Clinic, as well as the BFI. The BFI is based on family systems (Minuchin et al., 1975) and social-cognitive (Bandura, 1998) theories. Each dyad will participate in simultaneous, but separate, 75-minute parent and child groups over a 3 month period. The groups will start off meeting every week for 8 weeks and then bi-weekly for 1 month. Thus, dyads will attend a total of 10 group meetings over the 3 month period (12.5 hours of total treatment contact).
Study NCT00205712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Ketamine without dexmedetomidine
Study NCT00205712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Ketamine plus dexmedetomidine
Study NCT03887039 — intervention group
Intervention type: OTHER
Intervention: clinical examination
Description: clinical examination for all the oral findings
Study NCT02515539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardiAQ TMVI System (Transapical & Transfemoral DS)
Description: CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System
Study NCT02510911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg)
Description: Patients after laparoscopic colectomy will receive 3 times daily capsules with 100 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement.
Study NCT02510911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Description: Patients after laparoscopic colectomy will receive 3 times daily capsules with 200 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement.
Study NCT02510911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: corn starch (250 mg approx.)
Description: Patients after laparoscopic colectomy will receive 3 times daily capsules with 250 mg corn starch together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement.
Study NCT02510911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiopaque marker
Description: On the morning of the first, second and third day after surgery patients will take 1 capsule each day with radiopaque markers .~On day 4 after surgery an abdominal X-ray will be performed to localize the markers.~Each gelatin capsule contains 10 markers consisting of polyurethane encapsulated barium sulfate (40%).
Study NCT02510911 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Radiopaque marker
Description: On the morning of the first, second and third day after surgery patients will take 1 capsule each day with radiopaque markers .~On day 4 after surgery an abdominal X-ray will be performed to localize the markers.~Each gelatin capsule contains 10 markers consisting of polyurethane encapsulated barium sulfate (40%).
Study NCT03091803 — intervention group
Intervention type: DEVICE
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo GOCART DCE MRI
Study NCT03091803 — intervention group
Intervention type: DRUG
Intervention: Gadobenate Dimeglumine
Description: Given IV
Study NCT03091803 — intervention group
Intervention type: DRUG
Intervention: Gadoterate Meglumine
Description: Given IV
Study NCT03091803 — intervention group
Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Undergo QSM and T1WI imaging
Study NCT00120432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% tropicamide and 10% phenylephrine
Description: single dose vs three doses of 1%tropicamide and 10%phenylephrine
Study NCT00568464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VCR, CTX, ADM; IFO, VP-16
Description: VCD: VCR 2 mg d1, CTX 1200 mg/m2 d1, Mesna 240 mg/m2 tid d1, ADM 75mg/m2 d1, G-CSF 300 ug/d d5-11; IE: IFO 1800mg/m2 d1-5,Mesna 360 mg/m2 tid d1-5,VP-16 100 mg/m2 d1-5,G-CSF 300 ug/d d6-12; q3w. Surgery or radiation will be done to the patients with local diseases after four cycles of VCD/IE.
Study NCT02181634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel and Gemcitabine
Description: Nab-Paclitaxel will be administered first, at a dose of 125 mg/m² IV over a period of 30 minutes; gemcitabine will be administered second, at a dose of 1000 mg/m² over a period of 30 minutes.
Study NCT03541356 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Delivered via the I231 POD (Precision Olfactory Delivery) device
Study NCT02206126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy Restriction
Description: The energy restriction group was instructed to follow an energy-restricted diet (-800 kcal/day).
Study NCT03649672 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOF Watch SX
Description: Neuromuscular monitoring via the TOF Watch SX device
Study NCT03649672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOF Watch SX
Description: Neuromuscular monitoring via the TOF Watch SX device
Study NCT00282646 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraarterial stem cell therapy
Description: catheter delivery of stem cells
Study NCT00282646 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: intraarterial stem cell therapy
Description: catheter delivery of stem cells
Study NCT00282646 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stem cells
Description: intraarterial application of bone marrow mononuclear cells versus placebo
Study NCT00282646 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stem cells
Description: intraarterial application of bone marrow mononuclear cells versus placebo
Study NCT03934346 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Zinc amino acid complex
Description: Zinc in the form of a Zinc Amino Acid Complex (ZnAA) is provided with a test diet, and the amount of zinc that dissociates from the ZnAA and is thus absorbed via an ionic zinc transport pathway is determined based on the Hill transport kinetics for the respective subject.
Study NCT03699332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium-111-DOTA-Labetuzumab-IRDye800CW injection
Description: Tracer injection
Study NCT03699332 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SPECT/CT scan
Description: Abdominal and thoracic SPECT/CT scan.
Study NCT03699332 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CRS extended with dual-modality imaging
Description: cytoreductive surgery will be performed extended with the use of dual-modality imaging.
Study NCT02090725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3-4 Diaminopyridine
Study NCT01328184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel
Description: multiple doses
Study NCT01328184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel
Description: multiple doses
Study NCT01328184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinylestradiol
Description: multiple doses
Study NCT03541356 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: L-dopa 35 mg
Description: Delivered via the I231 POD (Precision Olfactory Delivery) device via one puff to one nostril
Study NCT03541356 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: L-dopa 70mg
Description: Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
Study NCT01328184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Microgynon + BI 10773
Description: multiple doses BI 10773
Study NCT01328184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol
Description: multiple doses